Press Releases

An Open End-of-Year Appreciation Letter

To All Our Esteemed Clients – New and Old – and Prospective Partners & Collaborators: Dear Colleagues and Friends, As the end of this year draws near, we at The Lynx Group would like to take this opportunity to thank all of you for an amazing 2020. We also share [ Read More ]

AONN+ Granted Membership in the American College of Surgeons Commission on Cancer

CRANBURY, NJ – The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeons Commission on Cancer (CoC). “It’s an honor to be selected for Commission on Cancer membership,” says Lillie Shockney, RN, BS, MAS, program [ Read More ]

ONCO360 Announces Hiring of Bill Gittinger; National Director of Managed Care

New York – June 26, 2014 – Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business. Mr. Gittinger will be joining an already accomplished Managed Care Sales team at [ Read More ]

IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®

New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network ofIMBRUVICA™ (ibrutinib). IMBRUVICA™ is now also indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL), who have received [ Read More ]

MekinistTM (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®

New York – January 16, 2014– The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage)1. Both Mekinist and Tafinlar are only available in limited distribution, and Onco360 is one of the [ Read More ]

PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform

PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform Onco360 Expected to Rapidly Grow Revenues Over the Next Several Years LOUISVILLE, Ky. and NEW YORK – December 9, 2013 – PharMerica Corporation’s (NYSE: PMC), a leading institutional pharmacy, specialty infusion and hospital services company [ Read More ]